bluebird bio Inc (BLUE.OQ)
19 Jan 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2011||Independent Chairman of the Board|
|44||2010||President, Chief Executive Officer, Director|
|51||2017||Chief Financial Officer, Principal Financial Officer and Strategy Officer|
|49||2016||Chief Operating Officer|
|39||2017||Principal Accounting Officer, Vice President - Finance|
- Bluebird to seek approvals for three treatments by end of 2019
- CORRECTED-Bluebird to seek approvals for three treatments by end of 2019
- BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019
- BRIEF-Merck And Bluebird Bio Sign Supply Agreement For Commercial Production Of Viral Vectors
- BRIEF-Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share